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Introduction: Recent studies have demonstrated that first-line treat-
ment with gefitinib, an epidermal growth factor receptor (EFGR)–
targeted tyrosine kinase inhibitor, is significantly superior to standard 
chemotherapy for advanced non–small-cell lung cancer (NSCLC) 
harboring EGFR sensitive mutations. Meanwhile, the efficacy of 
gefitinib therapy among elderly populations diagnosed with EGFR-
mutated NSCLC has not yet been elucidated. The purpose of this 
study was to investigate the efficacy and feasibility of gefitinib for 
chemotherapy-naive patients aged 75 or older with NSCLC harbor-
ing EGFR mutations; generally, these patients have no indication for 
treatment with platinum doublets.
Methods: Chemotherapy-naive patients aged 75 years or older with 
performance status 0 to 1 and advanced NSCLC harboring EGFR 
mutations, as determined by the peptide nucleic acid-locked nucleic 
acid polymerase chain reaction clamp method, were enrolled. The 
enrolled patients received 250 mg/day of gefitinib orally.
Results: Between January 2008 and May 2009, 31 patients were 
enrolled, all of whom were eligible. The median age was 80 (range, 
75–87) years. Twenty-five patients (81%) were women, and 30 patients 
(97%) had adenocarcinoma. The overall response rate was 74% (95% 
confidence interval, 58%–91%), and the disease control rate was 90%. 
The median progression-free survival was 12.3 months. The common 
adverse events were rash, diarrhea, and liver dysfunction. One treat-
ment-related death because of interstitial lung disease occurred.
Conclusions: This is the first study that verified safety and effi-
cacy of first-line treatment with gefitinib in elderly patients having 
advanced NSCLC with EGFR mutation. Considering its strong anti-
tumor activity and mild toxicity, first-line gefitinib may be preferable 
to standard chemotherapy for this population.
Key Words: Non–small cell lung cancer, Epidermal growth factor 
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Non–small-cell lung cancer (NSCLC), which accounts for 80% of lung cancer, remains the major cause of cancer-
related death in both Western and Asian countries. With pro-
longation of life expectancy, both the incidence and mortality 
of lung cancer in the elderly are rising. In Japan, 48 500 indi-
viduals aged 70 years or older were estimated to die of lung 
cancer in 20091; moreover, the ratio of elderly patients dying 
from lung cancer increased from 57% in 1989 to 72% in 2009. 
Treatment strategy in elderly patients with lung cancer has, 
thus, become an important issue.
About half of the newly diagnosed NSCLC patients 
have advanced disease, with no indication for local therapy 
such as surgery and radiotherapy. Chemotherapy for the 
elderly shows similar efficacy to that observed in younger 
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patients. However, it is generally more toxic, in terms of both 
incidence and severity, because of age-related weakening of 
organ function.2 Consequently, standard chemotherapy for 
elderly NSCLC patients, especially those aged 75 years or 
older, is performed as monotherapy with vinorelbine, gem-
citabine, or docetaxel instead of platinum doublets, which are 
the standard for younger patients.3–7 Although a recent phase 
III study suggested that the platinum doublet of monthly 
carboplatin and weekly paclitaxel may be superior to the 
gemcitabine or vinorelbine monotherapy in the elderly popu-
lation, the treatment-related death rate of the doublet group 
was determined to be 7%.8 Thus, investigation into safer 
and more effective treatments for elderly NSCLC patients is 
required.
Gefitinib, an orally administered tyrosine kinase inhib-
itor (TKI) of the epidermal growth factor receptor (EGFR), 
is a key molecularly targeted drug used for the treatment of 
advanced NSCLC. In May 2004, seminal studies showed 
that the presence of somatic mutations in the kinase domain 
of EGFR strongly correlated with increased responsive-
ness to EGFR TKIs in patients with NSCLC.9,10 Before this 
observation, it had been known that subgroups of NSCLC 
patients, including those of Asian race, female sex, non-
smoking status, and having adenocarcinoma, displayed sig-
nificant responses to gefitinib.11,12 These subgroups turned 
out to have a high incidence of EGFR mutations.13 Recently, 
two phase III studies comparing gefitinib treatment with che-
motherapy in chemo-naive patients selected on the basis of 
EGFR mutations were reported from Japan.14,15 These stud-
ies revealed the superiority of gefitinib treatment over stan-
dard chemotherapy by demonstrating that first-line gefitinib 
administration doubled progression-free survival (PFS) as 
compared with standard chemotherapy. One of two studies 
we conducted, namely the NEJ002 study, demonstrated that 
treatment with gefitinib provided patients with a better qual-
ity of life as compared with chemotherapy.16 The eligibility 
criteria in these studies was limited to patients aged 75 years 
or younger, as the treatments with platinum doublets were 
considered to be inappropriate for more elderly populations 
because of increased toxicity. Moreover, it has been reported 
in Japan that this more elderly group of patients develop 
interstitial lung disease (ILD) frequently when treated with 
gefitinib.17 In previous studies, we demonstrated that patient 
selection by EGFR mutation can dramatically improve the 
risk–benefit balance of gefitinib treatment; however, no 
study thus far has investigated the efficacy and feasibility 
of first-line gefitinib treatment in elderly NSCLC patients 
with EGFR mutation. Thus, the current phase II study was 
conducted.
METHODS
Patient Selection
This multicentric phase II study was approved by the 
institutional review board of each participating institute. The 
main eligibility criterion was to select chemotherapy-naive 
patients with NSCLC harboring sensitive EGFR mutations. 
Namely, patients with exon 19 deletions, L858R, L861Q, 
G719A, or G719S were included, but those with a resis-
tant T790M mutation were excluded. Patients who were 75 
years of age or older with Eastern Cooperative Oncology 
Group performance status (PS) 0 to 2 were also deemed eli-
gible. Other eligibility requirements were stage IIIB to IV or 
postoperative recurrent NSCLC, presence of a measurable 
lesion according to the Response Evaluation Criteria in Solid 
Tumors (RECIST), adequate organ function including liver 
function (aspartate transaminase and alanine aminotrans-
ferase ≤100 U/liter, total bilirubin <2.0 mg/dL), and written 
informed consent.
EGFR Mutation
Cytological or histological specimens were exam-
ined for EGFR mutation by the peptide nucleic acid-locked 
nucleic acid polymerase chain reaction (PCR) clamp 
method.18 Briefly, genomic DNA fragments containing muta-
tion hot spots of the EGFR gene were amplified via PCR in 
the presence of a peptide nucleic acid clamp primer synthe-
sized from a peptide nucleic acid with a wild-type sequence. 
This method leads to preferential amplification of the mutant 
sequence, which is then detected by a fluorescent primer that 
incorporates locked nucleic acids to increase the specificity. 
As a result, the mutant EGFR sequence is detected in spec-
imens that contain 100 to 1000 excess copies of wild-type 
EGFR sequence. The sensitivity and specificity of the peptide 
nucleic acid-locked nucleic acid PCR clamp method are 97% 
and 100%, respectively.
Drug Administration
Gefitinib was administered orally once a day at a dose 
of 250 mg. Patients continued to receive gefitinib until pro-
gression of disease, occurrence of intolerable severe toxicity, 
or withdrawal of consent. When severe toxicity was observed, 
patients were allowed to receive a reduced dose of gefitinib in 
accordance with the protocol.
Treatment Assessment
Complete response (CR), partial response (PR), stable 
disease (SD), and progressive disease (PD) were determined 
based on RECIST version 1.0. The primary end point of 
this study was overall objective response rate (ORR), which 
was the rate of patients with CR + PR; secondary end points 
were PFS, overall survival (OS), and toxicities. Computer 
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tomography (CT) scans were taken every month until CR or 
PR was observed. CR and PR required confirmation via reas-
sessment no earlier than 4 weeks after the first assessment 
meeting the criteria for response. After the confirmation, CT 
scans were taken every other month until PD was observed. 
The CT films of all patients were extramurally reviewed for 
confirmation of response. PFS was defined as the time from 
the date of randomization to the first observation of disease 
progression or death. OS was defined as the time from the 
date of randomization to the date of death or the most recent 
follow-up. Toxicities were evaluated according to the National 
Cancer Institute Common Toxicity Criteria (NCI-CTC) ver-
sion 3.0.
Statistical Consideration
Sample size was determined using the data as fol-
lows. Response rates greater than 70% had been previously 
observed in nonage-restricted patients with EGFR-mutated 
NSCLC.15 Meanwhile, clinical studies with elderly patients 
that investigated the efficacy of first-line chemotherapies in 
Japan showed ORR of 28% to 55%.7,19  Thus, we assumed that 
an ORR of more than 55% was clinically useful, whereas an 
ORR of less than 30% was not clinically useful. With α = 0.05 
and β = 0.1, the number of patients required was 27. Allowing 
10% loss in follow-up, a total of 30 patients were planned for 
enrollment.
All enrolled patients were evaluated for efficacy of 
received regimen. All patients treated with gefitinib, even for 
a short period of time, were entered into safety analysis.
RESULTS
Patient Characteristics
Between January 2008 and May 2009, a total of 31 
patients were enrolled. Baseline characteristics are described 
in Table 1. The median age at the time of enrollment was 80.3 
years (range, 75–89 years); 52% of the patients were over the 
age of 80. Of the 31 patients enrolled, 25 (81%) were women 
and 2 (6%) had a PS of 2. Histological types were all adeno-
carcinoma except for one adenosquamous carcinoma. There 
were 7 patients (23%) with stage IIIB, 22 (71%) with stage IV, 
and 2 (6%) with postoperative recurrence.
Efficacy
The ORR was 74.2% (95% confidence interval [CI], 
57.9%–90.5%); one patient had CR, and 22 patients had PR. 
Five of the remaining 8 patients (16.1%) had SD, with the 
resulting disease control rate (CR + PR + SD) reaching 90.3% 
(Table 2). This result attained the primary end point by a wide 
margin. The median follow-up period at the time of analysis 
was 27.5 months. Of all 31 patients enrolled, 15 (48.3%) were 
alive and free from progression for at least 6 months. The 
median PFS was 12.1 months (Fig. 1A), the 1-year OS was 
83.9% (95% CI, 70.2%–97.6%), and 2-year OS was 58.1% 
(95% CI, 45.2%–70.9%). At the data cutoff point (December 
2010), 13 patients (41.9%) had died, and the median OS was 
33.8 months (Fig. 1B).
Safety and Toxicity
Toxicity data for all 31 patients are presented in Table 3. 
Nine patients (29%) had a grade 3 adverse event (AE); 1 had 
a grade 5 AE ILD, and died of respiratory failure. The most 
common hematologic AE was elevation of transaminases; 
grade 3 to 4 elevation occurred in three patients (19%). The 
most common nonhematologic AEs were rash in 21 patients 
(71%), diarrhea in 10 patients (32%), and appetite loss in 9 
patients (29%). Dose reduction was seen in 14 patients (45%). 
Incidence and severity of AEs were acceptable and compa-
rable with previous reports.13–15
Treatment After Progression of Disease
Patient management after the protocol treatment was 
retrospectively investigated. Any treatment was allowed after 
confirmation of PD. Gefitinib was continued in 10 of 20 
patients confirmed to have PD. Three patients were treated 
with monotherapies of cytotoxic agents, including vinorel-
bine, gemcitabine, or docetaxel, and one patient was given 
TABLE 1. Character
N = 31 (%)
Sex
 Women 6 19
 Men 25 81
Age
 Mean (SD) 80.3 (4.1)
 Range 75–89
Smoking status
 Nonsmoker 23 74
 Smoker 8 26
Performance status
 0 16 55
 1 13 39
 2 2 6
Stage
 IIIB 7 23
 IV 22 71
 Postop 2 6
Histology
 Adenocarcinoma 30 97
 Adenosquamous 1 3
TABLE 2.  Response Rate of Treatment With Gefitinib
Response N = 31 (%)
CR 1 3
PR 22 71
Stable disease 5 16
Progressive disease 3 10
Overall response rate (CR + PR) 23 74
95% confidence interval (57.9–90.5)
CR, complete response; PR, partial response.
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erlotinib. No patient was treated with platinum doublets. Six 
patients did not receive any second-line treatment.
DISCUSSION
This is the first study targeting elderly patients with 
EGFR-mutated NSCLC. In this study, gefitinib displayed 
remarkable efficacy without increased toxicity.
We have previously reported a single-arm phase II study 
in which gefitinib was administered to frail patients with poor 
PS or elderly patients who were unfit to undergo treatment 
with cytotoxic agents.20 In that study, the patients enrolled 
were 20 to 74 years old with a PS of 3 to 4, 75 to 79 years 
old with a PS of 2 to 4, and aged 80 years or older (super-
elderly) with a PS of 1 to 4. Patients older than 74 years of 
age accounted for 39% of the total enrolled patients but, nev-
ertheless, OS was 17.8 months (Table 4). The current study 
strengthened the conclusion of the previous one and provided 
more information with respect to the efficacy of gefitinib in 
elderly NSCLC patients with EGFR mutation.
We defined elderly patients as those who were 75 years 
old and older. Many studies and subgroup analyses were per-
formed by considering elderly cases as 70 years of age or older, 
especially in Western countries. We have regarded patients aged 
70 to 75 years as being treatable with platinum-based chemo-
therapy. In fact, patients in this age group were enrolled in the 
NEJ002 study and were able to withstand treatment with plati-
num doublet. Accordingly, we excluded this group of patients 
from enrollment in the present study. Considering the aging of 
population structures and the increased longevity in Japan, we 
thought that the candidate selection for this study was reasonable.
Currently, in elderly patients, single-agent chemotherapy 
with a third generation agent (vinorelbine, gemcitabine, 
or taxanes) is the recommended approach according to 
the American Society of Clinical Oncology guidelines.2–7 
Gefitinib, which is considered minimally toxic, is often selected 
for the treatment of advanced NSCLC in elderly patients. 
Crino et al. performed a randomized phase II study (Gefitinib 
Versus Vinorelbine in Chemotherapy-Naïve Elderly Patients 
With Advanced Non-Small-Cell Lung Cancer [INVITE]) of 
gefitinib versus vinorelbine treatment in 196 chemotherapy-
naive unselected elderly patients.21 There were no statistical 
differences between gefitinib and vinorelbine in terms of PFS, 
OS, and ORR. Their study showed obviously lower efficacy 
of gefitinib in nonselected patients, as compared with the 
results shown from our study of EGFR-mutated patients.22–24 
These differences in effectiveness among studies highlight 
the importance of selection of patients by EGFR mutation 
analysis when administrating gefitinib. Furthermore, in 
another study of gefitinib treatment in Japanese patients aged 
FIGURE 1. Progression-free survival and overall survival. 
Kaplan–Meier curves for progression-free survival are shown 
for the progression-free survival population (A), and Kaplan–
Meier curves for overall survival are shown in (B). In (A) 
and (B), tick marks indicate patients for whom data were 
censored.
TABLE 3. Safety—Hematologic and Nonhematologic 
Toxicity
NCI-CTC Grade
Grade  
3–4 (%)1 2 3 4 5
Hematologic adverse events
 Leukocytopenia 2 1 0 0 0 0
 Neutropenia 0 1 0 0 0 0
 Anemia 6 4 0 0 0 0
 Thrombocytopenia 2 1 0 0 0 0
 AST/ALT 7 2 6 0 0 19
 T-Bil 3 1 0 0 0 0
 Creatinine 5 1 0 0 0 0
 Hyperkalemia 7 0 0 0 0 0
Nonhematologic adverse events
 Pneumonitis 0 0 0 0 1a 3
 Rash 12 10 1 0 3
 Nail change 4 2 0 0 0
 Stomatitis 3 0 0 0 0
 Alopecia 3 0 0 0 0
 Appetite loss 7 2 1 0 3
 Nausea/vomiting 1 0 0 0 0
 Diarrhea 9 2 1 0 3
 Constipation 2 0 0 0 0
 Fatigue 4 1 0 0 0
NCI-CTC, National Cancer Institute Common. Terminology Criteria; AST, andro-
gen suppression therapy; ALT, alanine aminotransferase; T-Bil, total bilirubin.
 aTreatmant-related death.
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75 or older, which included about 40% of the patients who 
were examined for EGFR mutations and 14% of the patients 
with EGFR-mutated tumors, the response rate was only 25%.25 
Meanwhile, there have been a few studies of treatment for 
elderly unselected patients with erlotinib, which is supposed 
to be more toxic than gefitinib as the administered dose was 
set near the maximum tolerance dose.26,27 The response rates 
in these studies were 10% or less, which were similar to those 
from the gefitinib studies conducted in Western populations 
(Table 4). In the other Asian study, erlotinib was compared with 
vinorelbine treatment in patients aged 70 or older.28 That study 
demonstrated that erlotinib yielded a higher response rate and 
PFS than vinorelbine. The percentage of mutation-positive 
patients was 30% of those who were examined for EGFR 
mutations in the erlotinib group. This high proportion might 
have contributed to the better results of the erlotinib group. 
The treatment of unselected NSCLC patients with erlotinib 
was also as ineffective as with gefitinib. Efficacy results in 
patients selected by EGFR mutation in the current study 
were substantially superior to those observed in the studies of 
gefitinib or erlotinib with unselected cases. Surprisingly, the 
median PFS and 2 year-survival rate here were comparable 
with results obtained in NEJ002 (12.3 versus 10.8 months, 
58% versus 61%, respectively) despite the limited enrollment 
of an elderly population in this study. These two studies, 
namely NEJ002 and NEJ003, have very similar backgrounds 
as they were performed during almost the same time period at 
identical institutions. It was suggested that gefitinib displayed 
similar efficacy in elderly patients when compared with their 
younger counterparts (Table 4). Although the current phase 
II study could not verify whether gefitinib prolonged PFS in 
elderly patients in comparison with younger patients, gefitinib 
might still prove to be the most suitable agent for elderly 
patients with EGFR-mutated NSCLC.
Elderly patients generally have more comorbidities 
and lower organ function than younger patients. Treatment-
related toxicity in the elderly is a more significant issue than 
for younger patients. A subgroup analysis of BR.21 showed 
that elderly patients treated with erlotinib displayed similar 
efficacy with respect to survival and quality of life as their 
younger counterparts but experienced greater toxicity.27 In 
the current study, toxicity was generally mild and predictable. 
Rash, diarrhea, and elevation of transaminase were observed 
frequently, similar to other studies with EGFR-TKIs. The 
single case of treatment-related death that occurred in our 
study was because of ILD, although this condition was not 
found in other patients. The frequency of ILD in the current 
study was comparable with that previously reported in Japan. 
Unfortunately, this patient did not respond to treatment with a 
large dose of corticosteroid, which is generally used for such 
conditions.17,29 Advanced age and smoking, preexisting ILD, 
and poor performance status have been reported as risk factors 
for ILD during treatment with gefitinib.17 Elderly patients 
treated with EGFR-TKIs should be monitored with further 
caution for ILD. On the whole, gefitinib was found to be a well-
tolerated therapy for elderly patients with mutated NSCLC.
In conclusion, first-line gefitinib treatment is highly 
effective with acceptable toxicity for elderly patients with 
advanced NSCLC harboring EGFR mutations. Together with 
our previous studies (NEJ001, NEJ002), gefitinib is shown 
to be an ideal therapy for all types of NSCLC patients with 
EGFR mutation.
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